BioPorto A/S says first quarter revenue increased by 33% driven by strong sales of antibodies and its NGAL test

The Danish company has forecast overall revenue of approximately DKK 30 (US$4.9 million) for 2021
BioPorto said that, in the first quarter, it pushed hard on clinical programs for its NGAL Test for pediatric acute kidney injury and a coronavirus test
BioPorto A/S (CPH:BIOPOR) (FRA:2P4) has shared an interim report which showed that its first-quarter 2021 revenue grew by 33% driven by “strong sales of antibodies” and its flagship NGAL acute kidney-injury test. 
The in-vitro diagnostic company based in Hellerup, Denmark, said that revenue from product sales of its proprietary NGAL Test remained at last year’s “high level” with a “solid performance” in the United States.

Related Keywords

California ,United States ,Denmark ,Hellerup ,Hovedstaden ,Danish ,Peterm Eriksen ,University Of California ,Drug Administration ,Emergency Use Authorization ,Pharma Biotech ,Bioporto ,Tcmkts Thoxf ,Roactiveinvestors ,கலிஃபோர்னியா ,ஒன்றுபட்டது மாநிலங்களில் ,டென்மார்க் ,ஹோவெட்ஸ்த்ததென் ,டேனிஷ் ,பல்கலைக்கழகம் ஆஃப் கலிஃபோர்னியா ,அவசரம் பயன்பாடு அங்கீகாரம் ,பார்மா பயோடெக் ,